Metronomic Oral Vinorelbine: An Alternative Schedule in Elderly and Patients PS2 With Local/Advanced and Metastatic NSCLC Not Oncogene-addicted

Background: The MILES and ELVIS studies showed that vinorelbine is one of the best options for elderly patients with advanced non-small-cell-lung cancer (NSCLC). Oral vinorelbine at standard schedule (60-80 mg/m²/weekly) has good activity in terms of response rates and progression-free survival. In...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :In Vivo
Главные авторы: ROSSI, DAVID, LIPPE, PAOLO, ROCCHI, MARCO BRUNO LUIGI, SARTI, DONATELLA, CATALANO, VINCENZO, GRAZIANO, FRANCESCO, GIORDANI, PAOLO, BALDELLI, ANNAMARIA, FEDELI, STEFANO LUZI, IMPERATORI, LUCA, LAICI, GIANLUCA, CAPPELLETTI, CLAUDIA, TAMBURRANO, TIZIANA, BRACCI, RAFFAELLA, ALESSANDRONI, PAOLO
Формат: Artigo
Язык:Inglês
Опубликовано: International Institute of Anticancer Research 2020
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7652434/
https://ncbi.nlm.nih.gov/pubmed/32871800
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12088
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы